STERIS plc (STE): Results of Operations and Financial Condition
STERIS plc (STE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2027 First Quarter • Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% • Fiscal 2027 first quarter as reported diluted EPS increased to $2.04; adjusted EPS per diluted share i
How this was made
The 30-second read
Why it matters
The key trading inputs are the combination of (1) Q1 operating and EPS beats versus prior year, (2) lower operating cash flow and free cash flow versus the prior-year quarter, (3) a $55M-$70M pre-tax restructuring charge range, and (4) updated capex to about $450M and free cash flow to about $800M while keeping full-year revenue growth and adjusted EPS guidance unchanged.
Market read
This is a primary earnings-and-guidance style disclosure with explicit cash flow, capex, and restructuring charge ranges, which can drive near-term repricing even with unchanged full-year EPS guidance.
What to watch
The restructuring completion is expected by fiscal 2030, so near-term earnings exclusion of charges may mask longer-term depreciation and labor impacts that could matter for subsequent quarters.
Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6%; as reported diluted EPS increased to $2.04; adjusted EPS per diluted share increased to $2.59.
Revenue, reported earnings, adjusted earnings and all three reported segments increased year over year, supported by stable underlying demand, Healthcare share gains and pricing. Cash flow declined year over year, while increased capital expenditure expectations and a restructuring program reduced expected free cash flow.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueGAAP | $1.5 billion | – | increased 7% |
| Constant currency organic revenue growthnon-GAAP | 6% | – | – |
| Net incomeGAAP | $200.1 million | – | – |
| Diluted EPSGAAP | $2.04 per diluted share | – | increased |
| Adjusted net incomenon-GAAP | $253.4 million | – | – |
| Adjusted EPSnon-GAAP | $2.59 per diluted share | – | increased |
| Healthcare operating incomeGAAP | $260.2 million | – | – |
| Applied Sterilization Technologies operating incomeGAAP | $142.9 million | – | – |
| Life Sciences operating incomeGAAP | $61.8 million | – | increased |
| Net cash provided by operationsGAAP | $367.1 million | – | – |
| Free cash flownon-GAAP | $279.6 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Healthcare10% improvement in service revenue, 9% growth in consumable revenue, and a 1% increase in capital equipment revenue; constant currency organic revenue growth was 6%. | $1.05 billion | – | grew 8% |
| Applied Sterilization Technologies (AST)6% growth in service revenue and a 13% decline in capital equipment revenue; constant currency organic revenue growth was 5%. | $297.6 million | – | increased 6% as reported |
| Life Sciences17% growth in capital equipment revenue, 8% improvement in consumable revenue, and 2% growth in service revenue; constant currency organic revenue increased 8%. | $146.7 million | – | increased 9% |
Fiscal 2027 outlook
- Revenueas reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7%
- NoteAdjusted earnings per diluted share are anticipated to be in the range of $11.10 to $11.30.
- NoteCapital expenditures are now anticipated to be approximately $450 million compared with prior expectations of $375 million.
- NoteFree cash flow is now expected to be approximately $800 million compared with prior expectations of $850 million.
- NoteTotal pre-tax restructuring charges of approximately $55 million to $70 million, consisting of approximately $40 million to $50 million of cash expenditures and approximately $15 million to $20 million of non-cash charges.
- NoteCompletion of the restructuring plan is anticipated to occur during fiscal 2030.
What drove it
- Management cited stable underlying demand.
- Healthcare performance was driven by share gains in consumables and services, with solid order growth for capital equipment.
- Healthcare operating income increased primarily due to improved volume, price, productivity and favorable mix, partly offset by inflation and increased tariff costs.
- AST operating income increased primarily on improved price, partly offset by increased depreciation and labor.
- Life Sciences operating income increased on price and volume, partly offset by inflation and lower productivity.
- The decline in operating cash flow and free cash flow was primarily driven by a significantly lower contribution from working capital, partly offset by higher net income.
Concerns
- Healthcare operating income faced inflation and increased tariff costs.
- AST capital equipment revenue declined 13%.
- Life Sciences productivity was lower.
- Net cash provided by operations and free cash flow declined from the prior-year period.
- Capital expenditures are now anticipated to be approximately $450 million compared with prior expectations of $375 million.
- The Company expects restructuring charges associated with consolidating formulated chemistries manufacturing and distribution to a new Center of Excellence in North Carolina.
What to watch
- Execution of the formulated chemistries Center of Excellence in North Carolina and the anticipated closure of facilities in St. Louis, Missouri, and Plymouth, Minnesota.
- Whether Healthcare service, consumable and capital-equipment growth continues.
- Whether AST capital equipment revenue improves following the reported 13% decline.
- Working-capital contribution and progress toward expected free cash flow of approximately $800 million.
- Inflation, increased tariff costs, labor costs and Life Sciences productivity.
Balance sheet and cash flow
- Net cash provided by operations was $367.1 million, compared with $420.0 million in the first quarter of fiscal 2026.
- Free cash flow was $279.6 million compared with $326.5 million in the prior year period.
Analysis
STERIS reported a solid fiscal 2027 first quarter. Total revenue increased 7% to $1.5 billion, and constant currency organic revenue growth was 6%. Reported net income was $200.1 million, or $2.04 per diluted share, compared with $177.4 million, or $1.79 per diluted share, in the prior-year quarter. Adjusted net income was $253.4 million, or $2.59 per diluted share, compared with $231.2 million, or $2.34 per diluted share.
All three reported segments delivered revenue growth. Healthcare revenue grew 8% to $1.05 billion, with services, consumables and capital equipment all growing. Management attributed the segment's operating-income improvement to volume, price, productivity and favorable mix, although inflation and increased tariff costs were offsets. AST revenue increased 6% to $297.6 million, supported by service revenue, while capital equipment revenue declined 13%. Life Sciences revenue increased 9% to $146.7 million, led by capital equipment revenue growth of 17%.
Segment operating income increased across Healthcare, AST and Life Sciences. Pricing was a driver in AST and Life Sciences, while Healthcare also benefited from volume, productivity and mix. The release identifies pressures from inflation, tariffs, labor, increased depreciation and lower Life Sciences productivity. These cost and productivity factors, together with the AST capital-equipment decline, are the main operating items requiring attention in subsequent periods.
Cash conversion was weaker year over year. Net cash provided by operations was $367.1 million compared with $420.0 million, and free cash flow was $279.6 million compared with $326.5 million. The Company attributed the decrease primarily to a significantly lower working-capital contribution, partially offset by higher net income. No capital-return activity, cash balance or debt balance was reported in the provided text.
The Company reiterated fiscal 2027 revenue-growth and adjusted-EPS expectations. It now anticipates capital expenditures of approximately $450 million compared with prior expectations of $375 million, and free cash flow of approximately $800 million compared with prior expectations of $850 million. STERIS also announced a targeted restructuring plan tied to a North Carolina formulated chemistries Center of Excellence, with expected total pre-tax restructuring charges of approximately $55 million to $70 million and completion anticipated during fiscal 2030.
Management, verbatim
We are pleased with our performance in the first quarter.
Dan Carestio, President and CEO of STERIS
Our first quarter results reflected stable underlying demand, while our commercial teams continue to drive meaningful growth within the Healthcare segment.
Dan Carestio, President and CEO of STERIS
Our revenue and earnings expectations for the year are unchanged, as the strength of our portfolio continues to enable us to help our Customers navigate a complex operating environment.
Dan Carestio, President and CEO of STERIS
Not in the filing
stated, not guessed- Total gross profit and gross margin
- Total operating income and operating margin
- Adjusted operating income and adjusted gross profit
- Income-tax expense and tax rate
- Prior-quarter comparisons for all reported metrics
- Total Company revenue by product category
- Balance-sheet cash balance
- Debt balance
- Share repurchases
- Dividends
- Capital-return amounts
- GAAP EPS guidance
- Gross-margin guidance
- Operating-expense guidance
- Tax-rate guidance
- Previous-release outlook for formal reported-results-versus-prior-guidance comparisons
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
STERIS filed an SEC 8-K with Exhibit 99.1 covering fiscal 2027 first-quarter results, a targeted restructuring tied to formulated chemistries consolidation, and updated capital expenditure and free cash flow expectations.
Ticker impact
STERIS reported fiscal 2027 Q1 results and reiterated guidance, while raising capex to about $450M tied to a new North Carolina formulated chemistries Center of Excellence.
Moderate volatility risk around the capex and restructuring details, with direction likely driven by how investors weigh unchanged EPS guidance versus lower Q1 cash flow and higher planned capex.
The filing provides fresh, decision-relevant datapoints: Q1 revenue/EPS, cash flow decline, restructuring charge range ($55M-$70M), and updated capex and free cash flow expectations. However, revenue and adjusted EPS guidance are unchanged, which can limit downside.
Market effects
Signals ongoing investment and restructuring in healthcare/life-sciences tools and consumables, potentially affecting peers’ sentiment around capex intensity and margin durability.
North Carolina facility buildout and closures in Missouri and Minnesota may shift regional industrial activity, but likely immaterial to broader markets.
Limited direct global read-through beyond healthcare infection prevention and sterilization supply chain demand stability.
Counterpoint
Investors may over-discount the cash flow decline because the company expects stronger full-year free cash flow offsetting higher capex, keeping the risk-reward closer to guidance than the headline capex number suggests.
Key entities
- companySTERIS plc
Reported fiscal 2027 first-quarter results, reiterated full-year guidance, and announced a restructuring and North Carolina Center of Excellence investment.
- executiveDan Carestio
CEO quoted on performance and unchanged revenue and earnings expectations.
%252FSteris%252520Corporation%252520logo%252520is%252520displayed%252520on%252520a%252520smartphone%252520screen_By%252520Rafael%252520Henrique.jpeg&w=2048&q=75)
